Tuesday - August 4, 2026
AstraZeneca: Tezspire Approved in the U.S. for Chronic Rhinosinusitis With Nasal Polyps
October 18, 2025
WILMINGTON, Delaware, Oct. 18 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation

*

AstraZeneca and Amgen's TEZSPIRE (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult an . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products